PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31175220-1	2019	Cabotegravir, a novel integrase inhibitor under development for treatment and prevention of HIV, is primarily metabolized by UDP-glucuronosyltransferase (UGT)1A1 and UGT1A9 to a direct ether glucuronide metabolite.	ether glucuronide	185-202	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	154-161
2492950-3	1989	This expressed UDPGT glycoprotein catalysed the glucuronidation of hyodeoxycholic acid forming an ether glucuronide.	ether glucuronide	98-115	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	15-20
31175220-1	2019	Cabotegravir, a novel integrase inhibitor under development for treatment and prevention of HIV, is primarily metabolized by UDP-glucuronosyltransferase (UGT)1A1 and UGT1A9 to a direct ether glucuronide metabolite.	ether glucuronide	185-202	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	166-172
23669385-8	2013	An inactive ether glucuronide, formed primarily via UGT1A1, was the principal biotransformation product at 18.9% of the dose excreted in urine and the principal metabolite in plasma.	ether glucuronide	12-29	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	52-58
21422672-10	2011	UGT1A6 and 1A8 were involved in the formation of the ether glucuronide only, whereas UGT1A7, 1A10 and 2B7 preferentially glucuronidated the carboxyl group.	ether glucuronide	53-70	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	0-6